Harvard Bioscience, Inc.HBIONASDAQ
Loading
Operating Expenses Over TimeContracting
Percentile Rank21
3Y CAGR-11.8%
5Y CAGR-4.3%
Year-over-Year Change
Expenses from normal business operations (SG&A, R&D, etc.)
3Y CAGR
-11.8%/yr
vs +2.2%/yr prior
5Y CAGR
-4.3%/yr
Recent deceleration
Acceleration
-13.9pp
Decelerating
Percentile
P21
Within normal range
vs 5Y Ago
0.8x
Contraction
Streak
3 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $46.51M | -23.7% |
| 2024 | $60.98M | -5.0% |
| 2023 | $64.18M | -5.3% |
| 2022 | $67.75M | +3.3% |
| 2021 | $65.59M | +13.4% |
| 2020 | $57.82M | -9.6% |
| 2019 | $63.95M | +2.8% |
| 2018 | $62.20M | +30.4% |
| 2017 | $47.70M | -3.7% |
| 2016 | $49.55M | - |